The current price of TXG is $59.31 — it has decreased by 12.16% since the previous close. Data as of Nov 5, 2026.
TXG is down 19.76% over the past week, down 39.53% over the past month and up 338.09% over the past year. The price is above its 200-day moving average of $41.23.
Analysts' average 12-month price target for TXG is $83.30, which implies 40.45% upside from the current price. Individual estimates range from $65.00 to $110.00.
Of the 18 analysts covering 10x Genomics, Inc., 1 rates it a strong buy, 5 rate it a buy and 12 rate it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
10x Genomics, Inc. has a market capitalization of $7.13B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, 10x Genomics, Inc. posted a loss of $0.14 per share against an estimate of -$0.2431, beating expectations by 42.41%. Upcoming reports are listed in the earnings calendar.
10x Genomics, Inc. reported revenue of $151.04M in its most recent quarter, which has decreased by 12.65% compared with the same quarter a year earlier. Analysts had expected $146.67M.
Companies most comparable to 10x Genomics, Inc. include Agilent Technologies, Inc., Illumina, Inc., Revvity, Inc., Bio-Techne Corporation and Qiagen N.V.
In the latest trading session TXG moved between $57.19 and $63.40, a range of 10.46% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of 10x Genomics, Inc. shows a sell rating today and a neutral rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks TXG has traded between $12.80 and $102.81. The current price is 42.31% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.